

Seegene begins exporting new COVID-19 variant tests worldwide

14 April 2021 | News

Seegene can produce 300,000 variant diagnostic test kits, with the capacity to test 30 million people per month



Seegene Inc., a biotech company specializing in molecular diagnostics, has announced that it has obtained an export permit from the Ministry of Food Safety and South Korean Pharmacist to begin shipping its COVID-19 variant tests to countries around the world. The leading biotech company said its supply of the coronavirus variant diagnostic test will renew global efforts to counter the pandemic, and help detect more contagious and deadly virus variants.

Seegene's latest COVID-19 variant tests, the "Allplex™ SARS-CoV-2 Master Assay" and "Allplex™ SARS-CoV-2 Variants I Assay" are exported to more than 20 countries around the world, including the European countries most affected by the pandemic such as the United Kingdom, Italy, Germany and France, in addition to Chile. Both variant diagnostic tests previously acquired CE-IVD marking in March this year.

Seegene stated that it has extensive production facilities previously established for mass manufacturing of its products. With this, it can produce 300,000 variant diagnostic test kits, making it possible to test 30 million people each month.

"Variant diagnostic testing (for COVID-19) will ease the burden on medical professionals around the world by achieving variant detection with a simple PCR test, enabling more comprehensive measures to prevent infections in managing the pandemic," said Dr. Jong-Yoon Chun, CEO of Seegene.

"Allplex™ SARS-CoV-2 Master Assay" is the world's first molecular diagnostic test capable of detecting COVID-19 and multiple variants of this virus simultaneously. The process takes less than 2 hours to complete and uses a unique real-time multiplex PCR test. Variants of the virus that this test can detect include B.1.1.7, B.1.351, and P.1. The "Allplex™ SARS-CoV-2 Master Assay" can also be used in conjunction with the "Allplex™ RV Essential Assay", a single-stage assay capable of detecting a total of 17 target viruses causing respiratory infections.

The assay can be used in conjunction with at least ten of Seegene's proprietary technologies that include the multiplex PCR method in mTOCE real-time™ a cutting-edge technology.